Table 1 Baseline characteristics of the TAH group and control group
|  | TAH group n = 1155 | Control group n = 3465 | P-value |
|---|---|---|---|
Age | 78.9 ± 7.5 | 78.6 ± 7.4 | 0.813 |
Sex, male | 469(40.6) | 1403(40.5) | 0.945 |
CCIS | 2.4 ± 1.9 | 1.2 ± 1.5 | < 0.001 |
 Myocardial infarction | 20(1.7) | 28(0.8) | 0.007 |
 Congestive heart failure | 318(27.5) | 544(15.7) | < 0.001 |
 Peripheral vascular disease | 61(5.3) | 113(3.3) | 0.002 |
 Cerebrovascular disease | 275(23.8) | 371(10.7) | < 0.001 |
 Dementia | 109(9.4) | 154(4.4) | < 0.001 |
 COPD | 260(22.5) | 350(10.1) | < 0.001 |
 Connective tissue disease | 28(2.4) | 31(0.9) | < 0.001 |
 Peptic ulcer disease | 276(23.9) | 366(10.6) | < 0.001 |
 CKD | 172(14.9) | 200(5.8) | < 0.001 |
 Hemiplegia | 18(1.6) | 19(0.6) | < 0.001 |
 Solid tumor | 104(9.0) | 187(5.4) |  |
 Liver disease | 74(6.4) | 113(3.3) | < 0.001 |
DM | 505(43.7) | 878(25.3) | < 0.001 |
Event |  |  | < 0.001 |
 None | 764(66.2) | 2788(80.5) |  |
 MACE | 128(11.1) | 254(7.3) |  |
 Death | 263(22.8) | 423(12.2) |  |
CV death | 19(1.6) | 20(0.5) | Â |
Medication | Â | Â | Â |
 ACEI | 91(7.9) | 276(7.8) | 0.925 |
 ARB | 819(70.9) | 2620(75.6) | 0.002 |
 CCB | 709(61.4) | 1753(50.6) | < 0.001 |
 α-blockers | 166(14.4) | 304(8.8) | < 0.001 |
 β-blockers | 318(27.5) | 840(24.2) | 0.025 |
 Furosemide | 265(22.9) | 365(10.5) | < 0.001 |
 Indapamide | 38(3.3) | 103(3.0) | 0.587 |
 Spironolactone | 58(5.0) | 72(2.1) | < 0.001 |
 Amiloride | 52(4.5) | 121(3.5) | 0.117 |
 NSAIDs | 429(37.1) | 1094(31.6) | 0.001 |
 TCA | 59(5.1) | 74(2.1) | < 0.001 |
 Diazepam | 117(10.1) | 182(5.3) | < 0.001 |
Follow up (years) | 3.5 ± 1.4 | 3.8 ± 1.4 | < 0.001 |